95 results
424B7
IMCR
Immunocore Holdings plc
5 Apr 24
Prospectus with selling stockholder info
4:34pm
a duty to obtain the highest value reasonably available to the shareholders.
Shareholder Litigation
Under English law, generally, the company, rather
S-3ASR
IMCR
Immunocore Holdings plc
20 Mar 24
Automatic shelf registration
8:51pm
a duty to obtain the highest value reasonably available to the shareholders.
Shareholder Litigation
Under English law, generally, the company, rather
8-K
EX-99.1
IMCR
Immunocore Holdings plc
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “believe”, “expect
8-K
EX-99.2
IMCR
Immunocore Holdings plc
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
but not limited to regulatory investigations and actions; litigation; fines and penalties; disruptions to our business operations; reputational harm; loss … global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer
10-K
EX-10.12
pl4dyhs ph48yyvpsnd3
28 Feb 24
Annual report
7:33am
10-K
EX-10.14
hki4o786
28 Feb 24
Annual report
7:33am
10-K
EX-10.13
7rfdgdp
28 Feb 24
Annual report
7:33am
8-K
8wpsl xsl
2 Feb 24
Immunocore Prices Upsized Convertible Senior Notes Offering
4:05pm
8-K
ys60vmv ke3p
29 Jan 24
Immunocore Announces Proposed Convertible Senior Notes Offering
5:06pm
8-K
EX-99.2
osn rlwdffo2
29 Jan 24
Immunocore Announces Proposed Convertible Senior Notes Offering
5:06pm
8-K
EX-99.2
dh3 l63j9
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
8-K
EX-99.1
xpbuouh4hsx3duyv
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
6-K
EX-99.3
busdf b2j
7 Nov 23
Current report (foreign)
7:09am
6-K
qptzq2on glrlpol
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.4
0vqyiw89ze11ey
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.3
jhzhdz vpwdu
10 Aug 23
Current report (foreign)
8:28am
6-K
8z16j2r4
10 Aug 23
Current report (foreign)
8:28am
6-K
wppdqnes
14 Jul 23
Current report (foreign)
4:21pm
6-K
80q0s8yzihe6ebswrcyt
5 Jun 23
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
9:20am